Arkolith/Insider Trading/JANX/Form 4

Meyer Andrew Hollman

Chief Business OfficerJanux Therapeutics, Inc. (JANX) · full profile →Form 4 · filed Jan 3, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$732K
Net Open-Market Flow
-$732K
Transactions
7
6 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 2, 2025Sell(S)6K$54.51$314K87K
Jan 2, 2025Sell(S)3K$53.76$157K93K
Jan 2, 2025Grant(A)18K—$095K
Jan 2, 2025Sell(S)1K$56.78$57K82K
Jan 2, 2025Sell(S)3K$55.76$192K83K
Jan 2, 2025Sell(S)200$57.37$11K82K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 2, 2025Grant(A)63K—$063K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-000554) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML